Bio‐AlcamidTMin drug‐induced lipodystrophy
Authors:
- Giuseppe SitoGSGiuseppe Sito
- Domenico CaporaleDCDomenico Caporale
- Nazzareno CammarotaNCNazzareno Cammarota
- 1 December 2003
- journal article
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 5 (3-4) , 226-230
Abstract
The development of new drugs to counter human immunodeficiency virus (HIV) infection has led to an increase in lipodystrophic syndrome among HIV-infected individuals receiving combination therapy. Bio-Alcamid(TM) is a recently developed polymeric substance that can be implanted to compensate for adipose effects. We have implanted this substance in 73 patients with up to three years' follow-up. The aesthetic results were deemed excellent by both physicians and patients. No implant dislocation, implant migration, granuloma, allergic reaction or intolerance were recorded.Keywords
This publication has 7 references indexed in Scilit:
- BIO-ALCAMID, A NOVEL PROSTHETIC POLYMER, DOES NOT INTERFERE WITH MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTICS OF HUMAN SKIN FIBROBLASTSPlastic and Reconstructive Surgery, 2003
- Lipodystrophy in Human Immunodeficiency Virus-Infected PatientsThe Journal of Clinical Endocrinology & Metabolism, 2002
- Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissueAIDS, 2002
- Facial Atrophy in HIV-Related Fat Redistribution Syndrome: Anatomic Evaluation and Surgical ReconstructionAnnals of Plastic Surgery, 2002
- Dermal filler materials and botulin toxinInternational Journal of Dermatology, 2001
- Strategies for treating HIV-related lipodystrophyExpert Opinion on Investigational Drugs, 2001
- Simultaneous Open Rhinoplasty and Alar Base Excision: Is There a Problem with the Blood Supply of the Nasal Tip and Columellar Skin?Plastic and Reconstructive Surgery, 2000